Builders FirstSource, Inc. (BLDR)
Whether directors and officers of Builders FirstSource, Inc. (BLDR) breached their fiduciary duties to the company and its shareholders.
Investigation
05/25/2022
Initial Lawsuit
07/26/2022
Lawsuit Progression
09/26/2022
Did Enochian Biosciences, Inc. (ENOB) mislead investors about crimes committed by its Chief Executive Officer (CEO) Gumrukcu? Did the company hide the truth about the alleged lack of credentials, murder-for-hire, and other white crimes?
This post is open for investors to gather facts, and findings and track their exposure to related lawsuits. We invite investors and shareholders to contribute to this investigation for their own benefit, add events to the factual timeline below and vote on events’ pertinence.
A lawsuit was subsequently filed. We will update this post as it unfolds.
06/01/2022
Hindenburg Research publishes a short thesis pointing out Gumrukcu’s criminal charges in Turkey, murder for hire, white collar crimes in California and the company’s dependence on entities he owns.
“. . . Gumrukcu has continued to sell unlicensed and unvetted “miracle” treatments to desperate parents of terminally ill children, bilking them of hundreds of thousands of dollars. His private practice’s office is located in the same building as Enochian’s headquarters, and its business is deeply intertwined with Enochian, despite the company’s claims to the contrary.
We have been unable to find any jurisdiction in which Gumrukcu is licensed as a medical doctor. He is unlicensed in California, where he has apparently been practicing medicine anyway, and where he has claimed to have made his major breakthroughs for Enochian.
Gumrukcu claims to have spent 12+ years earning an M.D. and multiple PhDs in Russia and Turkey. Our research indicates he made it all up. He has no medical degree and no PhDs. . .“
Stock Impact
Close | Previous close | Price variation | Percentage variation |
---|---|---|---|
$3.77 | $5.26 | $-1.5 | -28.42% |
A Enochian Biosciences, Inc. shareholder filed a federal securities class action lawsuit on behalf of a class consisting of all persons and entities (other than defendants) that purchased or otherwise acquired Enochian securities between September 24, 2020, and May 31, 2022, both dates inclusive.
According to the complaint, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, defendants allegedly failed to disclose to investors that:
(i) Gumrukcu was not a licensed doctor and had no verifiable degrees beyond high school;
(ii) accordingly, the scientific and technological underpinnings of Enochian’s product pipeline, purportedly invented by Gumrukcu, were dubious at best;
(iii) accordingly, the defendants had significantly overstated the commercial prospects for the company’s product pipeline;
(iv) Enochian’s senior leadership knew Gumrukcu had a criminal history that included fraud;
(v) accordingly, Enochian’s reliance on Gumrukcu, and its consulting and licensing agreements with G-Tech and SRI, subjected the company to a heightened risk of reputational and financial harm, as well as threatened the integrity of the company’s scientific findings; and
(vi) as a result, the company’s public statements were materially false and misleading at all relevant times.
The lead plaintiff deadline has passed, we will update this page as the lawsuit progresses
Whether directors and officers of Builders FirstSource, Inc. (BLDR) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Amicus Therapeutics, Inc. (FOLD) breached their fiduciary duties to the company and its shareholders.
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.
Whether directors and officers of Kewaunee Scientific Corporation (KEQU) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of LegalZoom.com, Inc. (LZ) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Inari Medical, Inc. (NARI) breached their fiduciary duties to the company and its shareholders.